-
Je něco špatně v tomto záznamu ?
Interleukin-4 induces a CD44 high /CD49b high PC3 subpopulation with tumor-initiating characteristics
HHH. Erb, F. Guggenberger, FR. Santer, Z. Culig,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
29236307
DOI
10.1002/jcb.26607
Knihovny.cz E-zdroje
- MeSH
- antigeny CD44 biosyntéza MeSH
- buňky PC-3 MeSH
- integrin alfa2 biosyntéza MeSH
- interleukin-4 metabolismus MeSH
- lidé MeSH
- nádorová transformace buněk metabolismus patologie MeSH
- nádorové proteiny metabolismus MeSH
- nádory prostaty metabolismus patologie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Pro- and anti-inflammatory cytokines may influence proliferation, migration, invasion, and other cellular events of prostate cancer (PCa) cells. The hyaluronan receptor CD44, which is regulated by Interleukin (IL)-4, is a prostate basal cell marker. CD44high /CD49bhigh expressing cells have been demonstrated to have tumor-initiating characteristics. Here, we aimed to analyze the effects of long-term IL-4 treatment on CD44/CD49b expression, migration, proliferation, and clonogenic potential of basal-like PCa cells. To this end PC3 cells were treated over 30 passages with 5 ng/mL IL-4 (PC3-IL4) resulting in an increased population of CD44high expressing cells. This was concurrent with a clonal outgrowth of cuboid-shaped cells, with increased size and light absorbance properties. Flow cytometry revealed that the PC3-IL4 CD44high expressing subpopulation corresponds to the CD49bhigh population. Isolation of the PC3-IL4 CD44high /CD49bhigh subpopulation via fluorescence-associated cell sorting showed increased migrative, proliferative, and clonogenic potential compared to the CD44low /CD49blow subpopulation. In conclusion, IL-4 increases a PC3 subpopulation with tumor-initiating characteristics. Thus, IL-4, similar to other cytokines may be a regulator of tumor-initiation and hence, may present a suitable therapy target in combination with current treatment options.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19001040
- 003
- CZ-PrNML
- 005
- 20200121143726.0
- 007
- ta
- 008
- 190107s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/jcb.26607 $2 doi
- 035 __
- $a (PubMed)29236307
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Erb, Holger H H $u Department of Urology and Pediatric Urology, University Medical Center Mainz, Mainz, Germany.
- 245 10
- $a Interleukin-4 induces a CD44 high /CD49b high PC3 subpopulation with tumor-initiating characteristics / $c HHH. Erb, F. Guggenberger, FR. Santer, Z. Culig,
- 520 9_
- $a Pro- and anti-inflammatory cytokines may influence proliferation, migration, invasion, and other cellular events of prostate cancer (PCa) cells. The hyaluronan receptor CD44, which is regulated by Interleukin (IL)-4, is a prostate basal cell marker. CD44high /CD49bhigh expressing cells have been demonstrated to have tumor-initiating characteristics. Here, we aimed to analyze the effects of long-term IL-4 treatment on CD44/CD49b expression, migration, proliferation, and clonogenic potential of basal-like PCa cells. To this end PC3 cells were treated over 30 passages with 5 ng/mL IL-4 (PC3-IL4) resulting in an increased population of CD44high expressing cells. This was concurrent with a clonal outgrowth of cuboid-shaped cells, with increased size and light absorbance properties. Flow cytometry revealed that the PC3-IL4 CD44high expressing subpopulation corresponds to the CD49bhigh population. Isolation of the PC3-IL4 CD44high /CD49bhigh subpopulation via fluorescence-associated cell sorting showed increased migrative, proliferative, and clonogenic potential compared to the CD44low /CD49blow subpopulation. In conclusion, IL-4 increases a PC3 subpopulation with tumor-initiating characteristics. Thus, IL-4, similar to other cytokines may be a regulator of tumor-initiation and hence, may present a suitable therapy target in combination with current treatment options.
- 650 _2
- $a nádorová transformace buněk $x metabolismus $x patologie $7 D002471
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a antigeny CD44 $x biosyntéza $7 D018960
- 650 _2
- $a integrin alfa2 $x biosyntéza $7 D039421
- 650 _2
- $a interleukin-4 $x metabolismus $7 D015847
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a nádorové proteiny $x metabolismus $7 D009363
- 650 _2
- $a buňky PC-3 $7 D000078722
- 650 _2
- $a nádory prostaty $x metabolismus $x patologie $7 D011471
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Guggenberger, Fabian $u Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
- 700 1_
- $a Santer, Frédéric R $u Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
- 700 1_
- $a Culig, Zoran $u Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Annés University Hospital Brno, Brno, Czech Republic.
- 773 0_
- $w MED00002577 $t Journal of cellular biochemistry $x 1097-4644 $g Roč. 119, č. 5 (2018), s. 4103-4112
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29236307 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20200121144103 $b ABA008
- 999 __
- $a ok $b bmc $g 1363980 $s 1039163
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 119 $c 5 $d 4103-4112 $e 20180119 $i 1097-4644 $m Journal of cellular biochemistry $n J Cell Biochem $x MED00002577
- LZP __
- $a Pubmed-20190107